Welcome to our dedicated page for Veradigm news (Ticker: MDRX), a resource for investors and traders seeking the latest updates and insights on Veradigm stock.
Veradigm Inc. (MDRX) is a healthcare technology company that focuses on healthcare data and technology solutions for providers, payers, and biopharma organizations. News about Veradigm often centers on how the company uses its platforms, data, connectivity, and expertise within the Veradigm Network to support clinical, operational, and financial performance in healthcare.
Investors and industry observers following MDRX news can expect updates on business performance, financing, and capital structure, as reflected in Veradigm’s announcements about financial outlooks, cash and debt levels, and debt financing arrangements. The company also issues news about its progress on financial reporting, including the filing of its Annual Report on Form 10-K with restated financial statements and its efforts to become current in SEC filings and pursue relisting on a national stock exchange.
Operational and client-focused news includes case studies and collaborations that highlight Veradigm’s role in value-based care, payer–provider integration, and revenue cycle management. Examples include recognition through a KLAS Points of Light Award for delivering insights at the point of care and announcements about organizations selecting Veradigm Revenue Cycle Services, Coding Services, and related offerings such as Veradigm Revenue Analytics, Veradigm Practice Management, and Veradigm Payerpath.
Veradigm also issues news on product and capability developments, such as applying artificial intelligence to deidentified EHR data to generate real-world evidence for GLP-1 therapies, and on thought leadership initiatives like the Smart Medicine Podcast. Governance and corporate updates, including leadership appointments and amendments to the company’s stockholder rights plan, are additional recurring themes. For a comprehensive view of MDRX-related developments, this news page aggregates these announcements and related coverage in one place.
Allscripts Healthcare Solutions (NASDAQ: MDRX) will report its Q3 2020 financial results after market close on October 29, 2020. A conference call and webcast detailing the results will follow at 4:30 PM ET. Investors can access the announcement on the company’s investor relations website. The earnings report marks a significant event for stakeholders as it provides insights into the company's financial health and operational performance during the quarter.
Allscripts (NASDAQ: MDRX) has completed the sale of its subsidiary, EPSi, to Strata Decision Technology for $365 million as of October 15. EPSi specializes in providing financial decision support tools for healthcare institutions. This strategic divestiture aligns with Allscripts' objectives to optimize its healthcare information technology offerings and streamline operations.
Allscripts (NASDAQ:MDRX) has announced the sale of its CarePort Health business to WellSky Corp. for $1.35 billion. This deal values CarePort at over 13 times its revenue and 21 times its non-GAAP Adjusted EBITDA. CarePort constitutes approximately 6% of Allscripts' consolidated revenues. The transaction is set to close by year-end, pending regulatory approvals. Proceeds from the sale will be utilized to enhance Allscripts' solutions, reduce debt, and support share repurchases. Management believes this move unlocks significant value for shareholders and allows a sharper focus on core operations.
Allscripts (NASDAQ: MDRX) continues to enhance healthcare interoperability through its dbMotion™ solution, which supports over 14M unique patient transactions monthly. The platform enables clinicians to access real-time patient data across various EHR systems, improving care outcomes globally. Recent achievements include sharing over 1B patient demographics and 650M observation results. Recognized by Frost & Sullivan as a leader in healthcare data interoperability, Allscripts aims to connect healthcare data to improve patient care and lower costs.